MetLife Investment Management’s Puma Biotechnology PBYI Stock Holding History

MetLife Investment Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$202K	Buy	24,873 +9,031	+57%	+$66.1K	﹤0.01%	2412
2026 Q1	$101K	Sell	15,842 -8,570	-35%	-$55.3K	﹤0.01%	2536
2025 Q4	$145K	Buy	24,412 +9,867	+68%	+$52.4K	﹤0.01%	2432
2025 Q3	$77.2K	Sell	14,545 -12,613	-46%	-$53.5K	﹤0.01%	2742
2025 Q2	$93.2K	Buy	27,158 +37	+0.1%	+$118	﹤0.01%	2581
2025 Q1	$80.3K	Buy	+27,121	New	+$84.9K	﹤0.01%	2610
2024 Q3	–	Sell	-10,973	Closed	-$35.8K	–	2877
2024 Q2	$35.8K	Buy	+10,973	New	+$48.2K	﹤0.01%	2819
2021 Q2	–	Sell	-2,392	Closed	-$23.3K	–	2474
2021 Q1	$23.3K	Sell	2,392 -11,399	-83%	-$127K	﹤0.01%	2301
2020 Q4	$141K	Hold	13,791	–	–	﹤0.01%	2150
2020 Q3	$139K	Hold	13,791	–	–	﹤0.01%	2066
2020 Q2	$144K	Hold	13,791	–	–	﹤0.01%	2074
2020 Q1	$116K	Hold	13,791	–	–	﹤0.01%	1993
2019 Q4	$121K	Hold	13,791	–	–	﹤0.01%	2231
2019 Q3	$148K	Hold	13,791	–	–	﹤0.01%	2106
2019 Q2	$175K	Sell	13,791 -27,582	-67%	-$635K	﹤0.01%	2109
2019 Q1	$1.6M	Buy	41,373 +27,582	+200%	+$842K	﹤0.01%	1384
2018 Q4	$281K	Hold	13,791	–	–	﹤0.01%	1723
2018 Q3	$632K	Hold	13,791	–	–	0.01%	1379
2018 Q2	$816K	Hold	13,791	–	–	0.01%	1122
2018 Q1	$938K	Hold	13,791	–	–	0.01%	1033
2017 Q4	$1.36M	Buy	+13,791	New	+$1.54M	0.02%	910

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's PBYI Position: Q2 2026 in Review

MetLife Investment Management increased its Puma Biotechnology (PBYI) stake by 57% in Q2 2026, buying an estimated $66.1K and bringing the position to 24,873 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

MetLife Investment Management first reported a position in PBYI in Q4 2017 and has held it in 21 quarters since. The position peaked at $1.6M in Q1 2019. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

MetLife Investment Management held 24,873 shares of Puma Biotechnology worth $202K as of Q2 2026.
MetLife Investment Management bought 9,031 Puma Biotechnology shares in Q2 2026, an estimated $66.1K.
Puma Biotechnology made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2412 holding.
MetLife Investment Management first reported a position in Puma Biotechnology in Q4 2017 and has held it in 21 quarters since.
MetLife Investment Management's Puma Biotechnology position peaked at $1.6M in Q1 2019.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.